Candidate: CoStAR-TIL

Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) drives distinct cytokine-mediated proliferation responses in CD4+ and CD8+ T cells.

Single cell RNA sequencing reveals functionally validated signatures of cytotoxicity in anti-FRá CoStimulatory Antigen Receptor (CoStAR™) activated CD4+ T cells.

A CD28/CD40 based chimeric costimulatory antigen receptor (CoStAR™) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes

Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities

ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors

Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma

Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies

Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients With Advanced Cutaneous Melanoma (ASGCT)

Costimulatory Antigen Receptor (CoStAR): A Novel Platform That Enhances the Activity of Tumor-Infiltrating Lymphocytes (SITC)

DELTA 1: A Global, Multicenter, Phase 2 Study of ITIL-168, an Unrestricted Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Adult Patients With Advanced Cutaneous Melanoma (SITC)